Suven Life Sciences receives four product patents for NCEs
These patents represent the NCEs for the treatment of disorders associated with neurodegenerative diseases. The four product patents, two from China, one from Mexico and one from New
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.